Pooled ADORING Analysis: Tapinarof Linked to Early Sleep Improvements in Pediatric AD

A pooled pediatric subanalysis from ADORING 1 and 2 was reported to show that once-daily tapinarof cream 1% versus vehicle was associated with early and sustained improvements in sleep-related patient-reported outcomes in children and adolescents with moderate-to-severe atopic dermatitis.

An Organon manufacturer news release reported that ADORING 1 and 2 enrolled adults and children aged 2 years and older and that the sleep analysis included children aged 2–17 years. These observations are described over an 8-week treatment period in the pooled dataset. The findings were sleep-domain changes tracked during the 8-week randomized period comparing once-daily tapinarof cream with vehicle.

The pooled sleep analysis drew 654 pediatric participants aged 2–17 years from ADORING 1 and ADORING 2. In the broader ADORING program, adults and children aged 2 years and older were enrolled (N=813) and randomized to once-daily tapinarof cream or vehicle for 8 weeks. Within that framework, investigators assessed sleep-related outcomes using the Patient-Oriented Eczema Measure (POEM) and the Dermatitis Family Impact (DFI) questionnaire, focusing on the sleep subdomains of each instrument. Results are framed as age-stratified comparisons of sleep-subdomain changes between active treatment and vehicle, setting up the timing and week-8 comparisons across pediatric age bands.

Differences in the POEM sleep subdomain were reported to emerge at different times by age: improvement versus vehicle was described as early as week 1 for children aged 2–6 years and for adolescents aged 12–17 years, while the corresponding signal was reported at week 4 for those aged 7–11 years. At week 8, the study reported mean POEM sleep-subdomain changes of −1.9 vs −0.9 (P<0.0001) for ages 2–6, −1.5 vs −1.0 (P=0.0029) for ages 7–11, and −1.2 vs −0.6 (P<0.0001) for ages 12–17. Across strata, the direction of the reported week-8 differences favored tapinarof relative to vehicle. The POEM sleep subdomain is one line of evidence for sleep-related changes in the pooled pediatric analysis.

Family impact was described in parallel: the report states that DFI sleep-subdomain findings showed statistically significant differences that favored tapinarof through week 8 across age groups. The study characterizes safety in the pooled pediatric analysis as consistent with prior studies. It also identifies folliculitis, headache, and nasopharyngitis as the most frequently reported treatment-emergent adverse events, using a threshold of ≥5% in any group.

According to the Organon news release, full results from the pooled analysis are scheduled for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 annual meeting in Philadelphia. The next public detail in this line of reporting is positioned as the forthcoming AAAAI 2026 presentation.